Risk of urinary tract infection in association with SGLT2 inhibitor therapy, as reported for network meta-analysis comparisons*
| Active | Drug and dose; odds ratio (95% credible interval) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cana_high | cana_low | dapa_high | dapa_low | empa_high | empa_low | ertu_high | ertu_low | ipra_high | ipra_low | placebo | remo_high | remo_low | tofo_high | tofo_low | |
| Active | 1.18 (0.94–1.48) | 1.29 (1.03–1.64) | 1.44 (1.15–1.79) | 1.20 (0.92–1.55) | 1.03 (0.87–1.24) | 1.11 (0.92–1.34) | 1.20 (0.90–1.61) | 1.00 (0.75–1.35) | 1.11 (0.56–2.21) | 1.11 (0.63–2.07) | 1.10 (0.93–1.31) | 0.81 (0.26–2.60) | 1.11 (0.36–3.62) | 1.68 (0.26–13.09) | 1.62 (0.30–10.50) |
| 0.84 (0.67–1.06) | cana_high | 1.10 (0.90–1.33) | 1.21 (0.92–1.56) | 1.01 (0.74–1.36) | 0.87 (0.68–1.10) | 0.94 (0.73–1.18) | 1.01 (0.73–1.45) | 0.85 (0.60–1.21) | 0.93 (0.46–1.95) | 0.94 (0.52–1.78) | 0.93 (0.75–1.15) | 0.68 (0.21–2.27) | 0.93 (0.30–3.06) | 1.41 (0.22–11.37) | 1.36 (0.26–9.43) |
| 0.77 (0.61–0.97) | 0.91 (0.75–1.11) | cana_low | 1.11 (0.84–1.45) | 0.92 (0.68–1.25) | 0.80 (0.63–1.01) | 0.86 (0.67–1.09) | 0.92 (0.66–1.32) | 0.77 (0.54–1.10) | 0.86 (0.41–1.79) | 0.86 (0.47–1.64) | 0.85 (0.68–1.06) | 0.62 (0.19–2.06) | 0.85 (0.27–2.83) | 1.28 (0.20–10.40) | 1.24 (0.24–8.50) |
| 0.70 (0.56–0.87) | 0.82 (0.64–1.09) | 0.90 (0.69–1.20) | dapa_high | 0.83 (0.66–1.05) | 0.72 (0.58–0.89) | 0.77 (0.62–0.96) | 0.84 (0.60–1.19) | 0.70 (0.50–0.99) | 0.77 (0.38–1.57) | 0.78 (0.43–1.44) | 0.77 (0.64–0.92) | 0.56 (0.18–1.86) | 0.77 (0.25–2.57) | 1.16 (0.18–9.72) | 1.13 (0.21–7.88) |
| 0.84 (0.65–1.09) | 0.99 (0.74–1.36) | 1.08 (0.80–1.48) | 1.20 (0.95–1.50) | dapa_low | 0.86 (0.67–1.13) | 0.92 (0.72–1.22) | 1.01 (0.70–1.47) | 0.84 (0.59–1.21) | 0.93 (0.44–1.94) | 0.93 (0.50–1.77) | 0.92 (0.73–1.17) | 0.68 (0.21–2.18) | 0.92 (0.29–3.12) | 1.40 (0.22–11.90) | 1.34 (0.25–10.04) |
| 0.97 (0.81–1.15) | 1.14 (0.91–1.46) | 1.25 (0.99–1.59) | 1.39 (1.12–1.72) | 1.16 (0.88–1.50) | empa_high | 1.07 (0.95–1.23) | 1.16 (0.87–1.59) | 0.97 (0.71–1.32) | 1.07 (0.53–2.17) | 1.08 (0.61–1.99) | 1.06 (0.94–1.22) | 0.78 (0.25–2.58) | 1.07 (0.34–3.53) | 1.62 (0.26–13.17) | 1.56 (0.29–10.59) |
| 0.90 (0.74–1.08) | 1.07 (0.84–1.36) | 1.17 (0.92–1.49) | 1.30 (1.04–1.60) | 1.08 (0.82–1.40) | 0.93 (0.82–1.06) | empa_low | 1.08 (0.80–1.48) | 0.91 (0.66–1.23) | 0.99 (0.49–2.04) | 1.00 (0.57–1.86) | 0.99 (0.87–1.13) | 0.73 (0.23–2.44) | 1.00 (0.32–3.30) | 1.50 (0.24–12.11) | 1.45 (0.27–9.83) |
| 0.83 (0.62–1.11) | 0.99 (0.69–1.37) | 1.08 (0.76–1.52) | 1.19 (0.84–1.67) | 0.99 (0.68–1.43) | 0.86 (0.63–1.15) | 0.93 (0.68–1.24) | ertu_high | 0.83 (0.63–1.11) | 0.92 (0.44–1.95) | 0.93 (0.51–1.82) | 0.92 (0.68–1.22) | 0.67 (0.21–2.28) | 0.92 (0.286–3.112) | 1.40 (0.22–11.11) | 1.35 (0.24–9.24) |
| 0.99 (0.74–1.34) | 1.18 (0.83–1.67) | 1.29 (0.91–1.85) | 1.43 (1.01–2.01) | 1.20 (0.82–1.70) | 1.03 (0.76–1.41) | 1.10 (0.82–1.52) | 1.20 (0.90–1.58) | ertu_low | 1.12 (0.52–2.29) | 1.11 (0.61–2.20) | 1.10 (0.82–1.47) | 0.81 (0.25–2.66) | 1.09 (0.35–3.65) | 1.67 (0.26–13.35) | 1.60 (0.29–11.40) |
| 0.90 (0.45–1.80) | 1.08 (0.51–2.20) | 1.17 (0.56–2.42) | 1.29 (0.64–2.65) | 1.07 (0.52–2.26) | 0.94 (0.46–1.88) | 1.01 (0.49–2.04) | 1.09 (0.51–2.26) | 0.90 (0.44–1.90) | ipra_high | 1.01 (0.54–1.92) | 1.00 (0.50–2.00) | 0.72 (0.20–3.13) | 0.97 (0.27–4.11) | 1.56 (0.21–12.19) | 1.52 (0.23–10.89) |
| 0.90 (0.48–1.60) | 1.06 (0.56–1.92) | 1.16 (0.61–2.12) | 1.29 (0.69–2.31) | 1.07 (0.57–1.99) | 0.93 (0.50–1.65) | 1.00 (0.54–1.76) | 1.07 (0.55–1.97) | 0.90 (0.46–1.65) | 0.99 (0.52–1.87) | ipra_low | 0.99 (0.54–1.75) | 0.72 (0.21–2.73) | 0.98 (0.29–3.73) | 1.53 (0.22–11.92) | 1.48 (0.25–9.62) |
| 0.91 (0.76–1.07) | 1.08 (0.87–1.34) | 1.17 (0.94–1.47) | 1.30 (1.09–1.57) | 1.08 (0.86–1.38) | 0.94 (0.82–1.06) | 1.01 (0.88–1.15) | 1.09 (0.82–1.47) | 0.91 (0.68–1.22) | 1.00 (0.50–2.01) | 1.01 (0.57–1.85) | placebo | 0.73 (0.23–2.42) | 1.00 (0.32–3.30) | 1.51 (0.24–12.14) | 1.47 (0.28–9.95) |
| 1.23 (0.38–3.93) | 1.46 (0.44–4.75) | 1.61 (0.48–5.14) | 1.77 (0.54–5.56) | 1.48 (0.46–4.80) | 1.28 (0.39–4.07) | 1.37 (0.41–4.34) | 1.49 (0.44–4.86) | 1.24 (0.38–4.04) | 1.39 (0.32–4.93) | 1.38 (0.37–4.80) | 1.36 (0.41–4.28) | remo_high | 1.34 (0.44–4.11) | 2.08 (0.24–22.26) | 1.92 (0.26–20.93) |
| 0.90 (0.28–2.79) | 1.08 (0.33–3.40) | 1.18 (0.35–3.68) | 1.30 (0.39–3.97) | 1.09 (0.32–3.50) | 0.93 (0.28–2.90) | 1.00 (0.30–3.12) | 1.09 (0.32–3.50) | 0.92 (0.27–2.89) | 1.03 (0.24–3.74) | 1.02 (0.27–3.41) | 1.0 (0.30–3.08) | 0.75 (0.24–2.28) | remo_low | 1.50 (0.17–16.43) | 1.42 (0.19–14.58) |
| 0.60 (0.08–3.85) | 0.71 (0.09–4.64) | 0.78 (0.10–4.95) | 0.86 (0.10–5.51) | 0.72 (0.08–4.62) | 0.62 (0.08–3.89) | 0.66 (0.08–4.18) | 0.71 (0.09–4.57) | 0.60 (0.08–3.82) | 0.64 (0.08–4.83) | 0.65 (0.08–4.54) | 0.66 (0.08–4.14) | 0.48 (0.04–4.21) | 0.67 (0.06–5.94) | tofo_high | 0.98 (0.40–2.37) |
| 0.62 (0.10–3.31) | 0.74 (0.11–3.93) | 0.81 (0.12–4.21) | 0.89 (0.13–4.76) | 0.74 (0.10–4.02) | 0.64 (0.09–3.41) | 0.69 (0.10–3.66) | 0.74 (0.11–4.14) | 0.62 (0.09–3.41) | 0.66 (0.09–4.39) | 0.68 (0.10–4.06) | 0.68 (0.10–3.59) | 0.52 (0.05–3.91) | 0.70 (0.07–5.29) | 1.02 (0.42–2.52) | tofo_low |
Note: SGLT2 = sodium glucose cotransporter-2 (where cana = canagliflozin, dapa = dapagliflozin, empa = empagliflozin, ertu = ertugliflozin, ipra = ipragliflozin, remo = remogliflozin, tofo = tofogliflozin, and for each drug, low = low dose, and high = high dose).
↵* Cells containing statistically significant results are indicated with shading.